I'll analyze the DLL3-targeted therapy landscape in ES-SCLC. Let me start by exploring the database.
{
"indications": {
"ES-SCLC": {
"targets": [
"DLL3",
"PD-L1",
"SEZ6"
],
"n_trials": 7
},
"Gastric/GEJ": {
"targets": [
"CLDN18.2",
"PD-1"
],
"n_trials": 7
},
"HER2+ Breast": {
"targets": [
"HER2"
],
"n_trials": 5
},
"HER2-low Breast": {
"targets": [
"HER2"
],
"n_trials": 1
}
}
}{
"count": 4,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
}
]
}Let me get the full records for these trials and check the broader ES-SCLC context (other targets) to understand competitive positioning.
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
}{
"count": 7,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05592184",
"sponsor": "Boehringer Ingelheim",
"drug": "BI 764532 (obrixtamig)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 180,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05950334",
"sponsor": "Legend Biotech",
"drug": "LB2102 (DLL3 CAR-T)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "CAR-T (autologous)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 40,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Dose-limiting toxicity / safety",
"control_arm": "Single arm"
},
{
"nct": "NCT04471727",
"sponsor": "AbbVie",
"drug": "ABBV-011 (SC-002 / SEZ6 ADC)",
"indication": "ES-SCLC",
"target": "SEZ6",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 130,
"start_year": 2020,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT03043872",
"sponsor": "Roche/Genentech",
"drug": "Atezolizumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 403,
"start_year": 2016,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03066778",
"sponsor": "AstraZeneca",
"drug": "Durvalumab + chemo",
"indication": "ES-SCLC",
"target": "PD-L1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 537,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}
]
}{
"sponsor_query": "Amgen",
"count": 2,
"trials": [
{
"nct": "NCT05060016",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE3",
"status": "RECRUITING",
"n_enroll": 600,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03319940",
"sponsor": "Amgen",
"drug": "Tarlatamab (AMG 757)",
"indication": "ES-SCLC",
"target": "DLL3",
"modality": "T-cell engager (BiTE)",
"phase": "PHASE2",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 220,
"start_year": 2018,
"line": "2L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}
]
}I now have a complete picture of the DLL3 landscape in ES-SCLC. Here's my analysis.
| Drug | Sponsor | Modality | Phase | Status | N | Start | Line | Primary EP | Control |
|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab (AMG 757) | Amgen | T-cell engager (BiTE) | 3 | Recruiting | 600 | 2022 | 2L+ | OS | Chemo |
| Tarlatamab (AMG 757) | Amgen | T-cell engager (BiTE) | 2 | Active, not recruiting | 220 | 2018 | 2L+ | ORR | Single arm |
| Obrixtamig (BI 764532) | Boehringer Ingelheim | T-cell engager (BiTE) | 2 | Recruiting | 180 | 2022 | 2L+ | ORR | Single arm |
| LB2102 | Legend Biotech | CAR-T (autologous) | 1 | Recruiting | 40 | 2023 | 2L+ | DLT/safety | Single arm |
Amgen is the unambiguous frontrunner, and the lead is structural, not incremental:
1. Modality split — BiTE vs. CAR-T. Three of four programs are off-the-shelf T-cell engagers (Amgen, BI). Legend's LB2102 is the outlier: an autologous DLL3 CAR-T. This is a fundamentally different bet — potentially deeper/more durable responses, but burdened by manufacturing logistics, lymphodepletion, and CRS/neurotoxicity management that limit scalability in a fast-progressing disease like SCLC. CAR-T against a solid tumor with heterogeneous antigen expression is also a higher-risk biology.
2. Endpoint ambition. Amgen has graduated to a hard outcome (OS) against an active control; BI is still at single-arm ORR; Legend is at safety/DLT. This maps directly onto regulatory readiness — Amgen is playing for approval, the others for proof-of-concept.
3. Trial scale. Enrollment tracks phase and ambition: 600 (Amgen P3) → 180–220 (P2) → 40 (Legend P1).
Every DLL3 asset here clusters in the same crowded 2L+ relapsed/refractory setting. The real opportunities sit in the gaps:
1L / maintenance — The biggest whitespace. The two completed Phase 3 standards (Roche's atezolizumab, AstraZeneca's durvalumab, both PD-L1 + chemo) own 1L, but with modest OS benefit. No DLL3 agent is being tested in the front line or as post-chemo maintenance — a natural expansion where DLL3 BiTEs could combine with or follow chemo-immunotherapy.
Combination with checkpoint inhibitors — Notably absent. With durvalumab/atezolizumab entrenched in 1L, a DLL3 BiTE + PD-L1 combination is an obvious untested strategy, especially given complementary mechanisms (T-cell redirection + checkpoint release).
Cross-target combinations / sequencing — SEZ6 (AbbVie's ABBV-011 ADC) is the other emerging SCLC target here. DLL3 BiTE + SEZ6 ADC, or sequencing across non-cross-resistant targets, is unexplored whitespace given SCLC's antigen heterogeneity.
Modality differentiation beyond BiTE — The BiTE lane is getting crowded (Amgen + BI head-to-head). Differentiated formats — DLL3 ADCs, half-life-extended or subcutaneous engagers with better CRS/therapeutic-window profiles, or allogeneic (off-the-shelf) cell therapy — represent room to compete on tolerability and convenience rather than being a fourth me-too BiTE.
Caveat: this analysis reflects only the trials in this database (4 DLL3 programs + 3 comparators). Notable real-world DLL3 efforts (e.g., earlier rovalpituzumab/DLL3 ADCs, and other engagers) aren't captured here, so the "whitespace" conclusions are scoped to what's represented in this dataset.
Would you like me to drill into the BiTE head-to-head (Amgen vs. BI design details) or map the full SCLC target landscape including SEZ6?
I now have a complete picture of the DLL3 landscape in ES-SCLC. Here's my analysis.
| Drug | Sponsor | Modality | Phase | Status | N | Start | Line | Primary EP | Control |
|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab (AMG 757) | Amgen | T-cell engager (BiTE) | 3 | Recruiting | 600 | 2022 | 2L+ | OS | Chemo |
| Tarlatamab (AMG 757) | Amgen | T-cell engager (BiTE) | 2 | Active, not recruiting | 220 | 2018 | 2L+ | ORR | Single arm |
| Obrixtamig (BI 764532) | Boehringer Ingelheim | T-cell engager (BiTE) | 2 | Recruiting | 180 | 2022 | 2L+ | ORR | Single arm |
| LB2102 | Legend Biotech | CAR-T (autologous) | 1 | Recruiting | 40 | 2023 | 2L+ | DLT/safety | Single arm |
Amgen is the unambiguous frontrunner, and the lead is structural, not incremental:
1. Modality split — BiTE vs. CAR-T. Three of four programs are off-the-shelf T-cell engagers (Amgen, BI). Legend's LB2102 is the outlier: an autologous DLL3 CAR-T. This is a fundamentally different bet — potentially deeper/more durable responses, but burdened by manufacturing logistics, lymphodepletion, and CRS/neurotoxicity management that limit scalability in a fast-progressing disease like SCLC. CAR-T against a solid tumor with heterogeneous antigen expression is also a higher-risk biology.
2. Endpoint ambition. Amgen has graduated to a hard outcome (OS) against an active control; BI is still at single-arm ORR; Legend is at safety/DLT. This maps directly onto regulatory readiness — Amgen is playing for approval, the others for proof-of-concept.
3. Trial scale. Enrollment tracks phase and ambition: 600 (Amgen P3) → 180–220 (P2) → 40 (Legend P1).
Every DLL3 asset here clusters in the same crowded 2L+ relapsed/refractory setting. The real opportunities sit in the gaps:
1L / maintenance — The biggest whitespace. The two completed Phase 3 standards (Roche's atezolizumab, AstraZeneca's durvalumab, both PD-L1 + chemo) own 1L, but with modest OS benefit. No DLL3 agent is being tested in the front line or as post-chemo maintenance — a natural expansion where DLL3 BiTEs could combine with or follow chemo-immunotherapy.
Combination with checkpoint inhibitors — Notably absent. With durvalumab/atezolizumab entrenched in 1L, a DLL3 BiTE + PD-L1 combination is an obvious untested strategy, especially given complementary mechanisms (T-cell redirection + checkpoint release).
Cross-target combinations / sequencing — SEZ6 (AbbVie's ABBV-011 ADC) is the other emerging SCLC target here. DLL3 BiTE + SEZ6 ADC, or sequencing across non-cross-resistant targets, is unexplored whitespace given SCLC's antigen heterogeneity.
Modality differentiation beyond BiTE — The BiTE lane is getting crowded (Amgen + BI head-to-head). Differentiated formats — DLL3 ADCs, half-life-extended or subcutaneous engagers with better CRS/therapeutic-window profiles, or allogeneic (off-the-shelf) cell therapy — represent room to compete on tolerability and convenience rather than being a fourth me-too BiTE.
Caveat: this analysis reflects only the trials in this database (4 DLL3 programs + 3 comparators). Notable real-world DLL3 efforts (e.g., earlier rovalpituzumab/DLL3 ADCs, and other engagers) aren't captured here, so the "whitespace" conclusions are scoped to what's represented in this dataset.
Would you like me to drill into the BiTE head-to-head (Amgen vs. BI design details) or map the full SCLC target landscape including SEZ6?
Deterministic summary over the curated trial set for the queried indication. A strong agent should recover the leaders, the phase/modality mix, and credible whitespace.
| Metric | Value | Note |
|---|---|---|
| Trials in scope | 7 | indication = ES-SCLC |
| By phase | PHASE1:2, PHASE2:2, PHASE3:3 | |
| By modality | T-cell engager (BiTE):3; Checkpoint inhibitor (mAb):2; CAR-T (autologous):1; Antibody-drug conjugate:1 | |
| Top sponsors | Amgen:2; Boehringer Ingelheim:1; Legend Biotech:1 | |
| Whitespace (modality @ line, no active trial) | Antibody-drug conjugate @ 1L; CAR-T (autologous) @ 1L; Checkpoint inhibitor (mAb) @ 1L; Checkpoint inhibitor (mAb) @ 2L+; T-cell engager (BiTE) @ 1L |